GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities ...

GSK is investing up to $800 million to double ... Through the addition of two new facilities, the project is set to bring on drug substance manufacturing and bolster the company's existing drug ...

A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

In the complaint, GSK argues Pfizer kicked off the project that led to Abrysvo no earlier than 2013, which it claims was at least seven years after its own RSV program. Up until recently ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

“So we see momentum on ABRYSVO, and we look forward to future ACIP updates,” Bourla added. GSK (GSK) continues to project £3B ...

the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced it is pledging $7.8million to the ‘Fund our Futures’ campaign led by the Global ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...

GSK said. “We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta ...

€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma ...